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Background: A substantial proportion of patients with coronary artery disease do not achieve
complete revascularization and continue to experience refractory angina despite optimal medi-
cal therapy. Recently, stem cell therapy has emerged as a potential therapeutic option for these
patients. However, findings of individual trials have been scrutinized because of their small
sample sizes and lack of statistical power. Therefore, we conducted an updated comprehensive
meta-analysis of available randomized controlled trials (RCTs) with the largest sample size ever
reported on this subject.
Hypothesis: In patients with chronic angina stem cell therapy improves clinical outcomes.
Methods: Scientific databases and websites were searched for RCTs. Data were independently
collected by 2 investigators, and disagreements were resolved by consensus. Data from 10 trials
including 658 patients were analyzed.
Results: Stem cell therapy improved Canadian Cardiovascular Society angina class (risk ratio:
1.53, 95% CI: 1.09 to 2.15, P = 0.013), exercise capacity (standardized mean difference [SMD]:
0.56, 95% CI: 0.23 to 0.88, P = 0.001), and left ventricular ejection fraction (SMD: 0.63, 95%
CI: 0.27 to 1.00, P = 0.001) compared with placebo. It also decreased anginal episodes (SMD:
–1.21, 95% CI: –2.40 to −0.02, P = 0.045) and myocardial perfusion defects (SMD: –0.70, 95%
CI: –1.11 to −0.29, P = 0.001). However, no improvements in all-cause mortality were
observed after a relatively short follow-up.
Conclusions: In patients with chronic angina on optimal medical therapy, stem cell therapy
improves symptoms, exercise capacity, and left ventricular ejection fraction. These findings
warrant confirmation using larger trials.
KEYWORDS
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1 | INTRODUCTION
The number of patients diagnosed with severe coronary artery dis-
ease is increasing because of improved survival rates and an aging
population.1 Despite continued developments and improvements in
treatments that facilitate myocardial revascularization, a substantial
proportion of these patients do not achieve complete revasculariza-
tion and continue to experience refractory angina despite optimal
medical therapy (OMT).1 Recently, several small randomized clinical
trials (RCTs) suggested that stem cell therapy may be a potential ther-
apeutic option for these patients.2–11 However, individual trials have
been criticized for their small sample sizes and resulting lack of
statistical power. Therefore, we conducted an updated comprehen-
sive meta-analysis of available RCTs.
2 | METHODS
2.1 | Data sources and searches
This meta-analysis was performed according to the guidelines of Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA).12 We performed computerized literature searches of the
PubMed, http://www.Clinicaltrials.gov, and Cochrane databases from
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their respective inceptions to November 2017 without language
restrictions. Searches were performed on various combinations of the
following terms: “cell therapy,” “stem cell,” “angina,” “ischemic heart
disease,” and “clinical trial.” In addition, abstracts from major interna-
tional cardiology scientific meetings were reviewed. We also con-
tacted corresponding authors for those articles not reporting mean
values for continuous variables.
2.2 | Data extraction and quality assessment
RCTs were included if patients suffering from angina despite OMT
were randomly assigned to either stem cell therapy or placebo treat-
ment. The data were independently collected by 2 investigators, and
disagreements were resolved by consensus. The potential risk of bias
of RCTs was appraised according to the Cochrane Collaboration
guidelines.13
The primary efficacy endpoints were changes in Canadian Car-
diovascular Society (CCS) angina class, anginal frequencies, and exer-
cise capacity. The secondary efficacy endpoints were left ventricular
ejection fraction (LVEF) and myocardial perfusion defects (summed
score) identified using single-photon emission computed tomography
(SPECT). Study definitions were used for the outcome data.
2.3 | Data synthesis and analysis
This meta-analysis was performed using the Comprehensive Meta-
Analysis system, version 3 (Biostat, Inc., Englewood, NJ). For dichoto-
mous variables, pooled risk ratios (RRs) were calculated using a
random-effects model. For continuous variables, the data were sum-
marized as the standardized mean difference (SMD) because the
measurement units for some of the outcomes varied across studies.
Because the trials by Pokushalov and Henry enrolled predominantly
ischemic cardiomyopathy patients, additional sensitivity studies were
performed excluding both trials.5,8 We evaluated the presence of
heterogeneity across trials using the Cochran Q test and the Higgins
I2 test.14 When heterogeneity was discovered, a sensitivity analysis
was performed by excluding 1 study at a time and evaluating the
impact on the summary results.15 Publication bias was not assessed
because the number of included trials was inadequate to properly
assess a funnel plot or to use more advanced regression-based
assessments.16
The authors are solely responsible for the design and conduct of
this study, all study analyses, the drafting and editing of the manu-
script, and its final contents. No extramural funding was used to sup-
port this work.
3 | RESULTS
Ten RCTs including 658 patients (386 in cell groups and 272 in pla-
cebo groups) met our inclusion criteria.2–11 All included RCTs were
blinded. The search flow diagram is shown in Figure 1. Table 1
describes the characteristics of each individual trial. The majority of
these trials were multicenter, but they included only a small number
of patients. Four studies used CD34+ cells, 3 used bone marrow
mononuclear cells, 2 used CD133+ cells, and 1 used adipose-derived
stem cells. The techniques used to harvest these cells varied among
the studies. The follow-up duration was 6 months in 5 studies,
12 months in 4 studies, and 24 months in 1 study.
In patients suffering from chronic angina, stem cell therapy
decreased anginal episodes (SMD: –1.21, 95% CI: –2.40 to −0.02,
P = 0.045) compared with the placebo-treated group (Figure 2). How-
ever, significant between-trial heterogeneity was found (Cochran's
Q = 115.8, P < 0.001, I2 = 96.54%). Sensitivity analysis suggests that
heterogeneity originated from the study by Wang, which was a
single-center study performed in China.4 Removing this trial elimi-
nated the heterogeneity (Cochran's Q = 2.9, P = 0.39, I2 = 0.00%)
FIGURE 1 Search flow diagram
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FIGURE 2 (A) Improvement in anginal episodes from baseline to the longest follow-up time point. (B) Individual and pooled RRs for
improvements in CCS angina class. (C) Improvement in exercise capacity from baseline to the longest follow-up time point. The size of the
square represents the relative impact of the corresponding study on the overall estimate. The overall summary estimate for the analysis is
marked with a diamond. The width of the diamond represents the 95% CI. Abbreviations: CCS, Canadian Cardiovascular Society; CI, confidence
interval; df, degrees of freedom; RR, risk ratio; std diff, standard difference
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without affecting summary results (SMD: –0.44, 95% CI: –0.66 to
−0.21, P < 0.001). On the other hand, removing any other trial did
not eliminate heterogeneity.
Similarly, significantly more patients in the stem cell–treated
group displayed improvements in their CCS angina class (RR: 1.53,
95% CI: 1.09 to 2.15, P = 0.013; Figure 2). There was no significant
heterogeneity between the trials (Q = 0.8, P = 0.93, I2 = 0.00%).
Stem cell treatment also increased exercise capacity (SMD: 0.56,
95% CI: 0.23 to 0.88, P = 0.001) compared with the placebo-treated
group (Figure 2). Again, significant heterogeneity was found
FIGURE 3 (A) Improvements in perfusion defects (by SPECT) from baseline to the longest follow-up time point. (B) Improvement in LVEF.
(C) Individual and pooled RRs for all-cause mortality. Abbreviations: CI, confidence interval; df, degrees of freedom; LVEF, left ventricular
ejection fraction; RR, risk ratio SPECT, single-photon emission computed tomography; std diff, standard difference
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(Cochran's Q = 14.6, P = 0.022, I2 = 59.14%), originating from the
study by Wang. Removing this study eliminated heterogeneity
(P = 0.52, I2 = 0.00%) without affecting summary results (SMD: 0.39,
95% CI: 0.17 to 0.61, P < 0.001).
Stem cell therapy also improved LVEF (SMD: 0.63, 95% CI: 0.27
to 1.00, P = 0.001; Figure 3). However, no effects on all-cause mor-
tality were found (RR: 0.47, 95% CI: 0.183 to 1.22, P = 0.121;
Figure 3). No between-trial heterogeneity was found for any of these
outcomes.
Finally, sensitivity analyses excluding the studies by Pokushalov
and Henry did not change our summary results or conclusion.5,8 In
addition, the incidence of adverse effects with stem cell therapy was
low, as shown in Table 2.
4 | DISCUSSION
In this meta-analysis of 10 RCTs, we evaluated the efficacy of stem
cell therapy in patients suffering from chronic angina. We found that
stem cell therapy improved the CCS angina class and decreased
angina frequency during 6 to 24 months of follow-up. The stem cell
therapy also improved exercise capacity, perfusion defects (observed
via SPECT), and LVEF.
Despite continued developments and improvements in treat-
ments facilitating myocardial revascularization, about 5% to 15% of
patients do not achieve complete revascularization and continue to
experience refractory angina despite OMT.1 Although it results in low
mortality, refractory angina is a debilitating condition. Thus, a new
therapy is needed for these patients. Recently, stem cell therapy has
emerged as a potential therapeutic option for these patients.1 Stem
cell therapy is thought to improve myocardial perfusion and angina
by promoting neovascularization.1 This may be partly due to the
capacity of stem cells to differentiate into endothelial cells and
smooth muscle.1 However, the predominant mechanism by which
stem cells act appears to be through the secretion of paracrine fac-
tors that have cryoprotective and angiogenic effects.17
Several small-sized RCTs and meta-analyses have suggested that
stem cell therapy may improve symptoms in patient with chronic
angina.2–10,18,19 However, since those meta-analyses, several new
RCTs have been reported, arguably rendering those meta-analyses
outdated.8–10 Our updated, comprehensive meta-analysis (consisting
of the largest sample size ever reported) showed that, in patients
with chronic angina, stem cell therapy improved symptoms and exer-
cise capacity. It also decreased perfusion defects measured by
SPECT. In addition, stem cell therapy was associated with a statisti-
cally significant improvement in LVEF. However, in the majority of
these trials, global left ventricular systolic function was preserved,
and the absolute improvement in LVEF with stem cell therapy was
small. Finally, because of the small sample sizes of these trials and
shorter follow-up periods, no definite conclusion can be made about
the impact of stem cell therapy on mortality. Therefore, additional tri-
als with larger sample sizes and longer follow-ups are needed.
4.1 | Study limitations
This meta-analysis has several limitations. First, we did not have indi-
vidual participant data; data from various studies were combined.20
Each study had its own protocol and definitions as well as follow-up
duration. Specifically, the type of stem cell, number of stem cells, and
delivery method varied across studies. However, because small num-
bers of patients participated in each trial, subgroup analyses to deter-
mine the relative efficacy between certain types of cells or routes of
administration were not performed. Therefore, additional studies
must be conducted to compare cell types and routes of administra-
tion. Similarly, the definition of major adverse cardiac events varied
across the studies, so we could not report on the effects related to
the major adverse cardiac events rate. In addition, not all studies
reported data about the class of angina and the number of episodes
of angina; we were accordingly unable to include data from all of the
TABLE 2 Incidence of serious adverse events by trial
Author, Year Cell Groups Placebo
Losordo, 2007 A-arrhythmia, 1; CHF, 16; respiratory arrest, 11; CVA, 5;
bleeding/anemia, 16; electrolytes disorder, 16
A-arrhythmia, 33; V-arrhythmia, 1
Tse, 2007 NR NR
Van Ramshorst, 2009 CHF, 4 PE, 4; CVA, 4; infection, 4; breast cancer, 4
Wang, 2010 A-arrhythmia, 2; V-arrhythmia, 2; angina exacerbation,
3; CVA, 2; endocrine/electrolyte disorder, 2
A-arrhythmia, 3; V-arrhythmia, 2; angina
exacerbation, 5; endocrine/electrolyte disorder, 2
Pokushalov, 2010 NR NR
Losordo, 2011 MI, 5; MACE, 12; stroke, 3; cardiac hospitalization
or ED visit, 32
MI, 12; MACE, 26; stroke, 1; cardiac hospitalization
or ED visit, 37
Jimenez-Quevedo, 2014 MACE and MACVE, 10; sustained VT/VF, 5; PE, 5;
repeat hospitalization for cardiac cause, 11
MACE and MACVE, 11; sustained VT/VF, 11;
repeat hospitalization for cardiac cause, 25
Henry, 2016 MACE, 35; MI, 5; stroke/TIA, 11; CHF hospitalization, 11 MACE, 21; stroke/TIA, 7; CHF hospitalization, 21
Posvic, 2016 MACE, 42; MI, 10; CV hospitalization, 32; V-arrhythmia, 7 MACE, 67; MI, 7; CV hospitalization, 64; V-arrhythmia, 3
Wojakowski, 2017 PFA, 6; UA, 6 DVT, 6; UA, 6
Abbreviations: A-arrhythmia, atrial arrhythmia; CHF, congestive heart failure; CV, cardiovascular; CVA, cerebrovascular accident; DVT, deep venous
thrombosis; ED, emergency department; MACE, major adverse cardiac events; MI, myocardial infarction; NR, none reported; PE, pericardial effusion;
PFA, pseudoaneurysm of femoral artery; TIA, transient ischemic attack; UA, unstable angina; V-arrhythmia, ventricular arrhythmia; VF, ventricular fibrilla-
tion; VT, ventricular tachycardia. Data are presented as %.
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trials to estimate the pooled effect of stem cell on anginal symptoms.
Finally, because the sample sizes of these trials were small, our find-
ings are hypothesis-generating, and additional trials with larger sam-
ples are needed. Despite these limitations, this is the most
comprehensive meta-analysis with the largest sample size ever
reported on this subject.
5 | CONCLUSION
In patients suffering from chronic angina, stem cell therapy signifi-
cantly improves symptoms, exercise capacity, and LVEF compared
with placebo-treated groups. It also decreases myocardial perfusion
defects. These findings warrant further studies in a larger clinical trial
in the future.
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